Exploration of Medicine

Table 1. List of clinical studies using indomethacin for COVID-19.

Studies	Design	Sample size	Comparator	Outcomes	Limitations
Clark C. 2020 [14]	Open	60	No one	Cough	Not peer review
Rajah R. 2020 [15]	Prospective	17	No one	Number of recovered patients	Not randomized
Fazio S. 2021 [28]	Observational retrospective	85	No one	Symptom duration	Not randomized
Krymchantowski A.V. 2022 [16]	Observational retrospective	37	No one	Headache	Not randomized
Ravichandran R. 2022 [29]	Open-label RCT	103 vs 107	Paracetamol	Patients requesting retrospective support	Open label

Return to article view

RCT: randomized controlled trial. The study by Fazio et al. [28] used indomethacin in the context of a therapeutic regimen with other substances.

Declarations

Author contributions

SF: Conceptualization, Data curation, Writing—original draft, Writing—review & editing. AD: Data curation, Writing—original draft, Writing—review & editing. PB: Data curation, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

SF and AD declare no conflict of interest. PB consulted with Vanda Omeopatici s.r.l. (Roma, Frascati), a company producing food supplements, which had no role in this manuscript.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

No new data were created or analyzed in this study. Data sharing does not apply to this article.

Funding

This research received no external funding.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268:2420–5. [DOI] [PubMed]

Phillips RS, Vaarwerk B, Morgan JE. Using Evidence-Based Medicine to Support Clinical Decision-Making in RMS. Cancers (Basel). 2022;15:66. [DOI] [PubMed] [PMC]

Martín-Masot R, Ochoa Sangrador C, Cuervo Valdés JJ, Blanco Rodríguez C, González Rodríguez P, González de Dios J; en representación del Comité de Trabajo de Pediatría Basada en la Evidencia. Evidence-based medicine: 5 steps to navigate uncertainty. An Pediatr (Engl Ed). 2025;103:503930. [DOI] [PubMed]

Barghash RF, Gemmati D, Awad AM, Elbakry MMM, Tisato V, Awad K, et al. Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies. Molecules. 2024;29:5564. [DOI] [PubMed] [PMC]

Carley S, Horner D, Body R, Mackway-Jones K. Evidence-based medicine and COVID-19: what to believe and when to change. Emerg Med J. 2020;37:572–5. [DOI] [PubMed]

Gozzo L, Longo L, Vitale DC, Drago F. The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience. Front Pharmacol. 2020;11:588132. [DOI] [PubMed] [PMC]

Scotto Di Vetta M, Morrone M, Fazio S. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations. World J Meta-Anal. 2020;8:173–7. [DOI]

Onyango OH. In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review. Adv Pharmacol Pharm Sci. 2023;2023:4562974. [DOI] [PubMed] [PMC]

Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616:673–85. [DOI] [PubMed]

10.

Chakraborty R, Bhattacharje G, Baral J, Manna B, Mullick J, Mathapati BS, et al. In-silico screening and in-vitro assay show the antiviral effect of Indomethacin against SARS-CoV-2. Comput Biol Med. 2022;147:105788. [DOI] [PubMed] [PMC]

11.

Amici C, Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11:1021–30. [PubMed]

12.

Abdolmaleki G, Taheri MA, Paridehpour S, Mohammadi NM, Tabatabaei YA, Mousavi T, et al. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. Daru. 2022;30:379–406. [DOI] [PubMed] [PMC]

13.

Xu T, Gao X, Wu Z, Selinger DW, Zhou Z. Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo. bioRxiv 2020.04.01.017624 [Preprint]. 2020 [cited 2026 Jan 9]. Available from: https://www.biorxiv.org/content/10.1101/2020.04.01.017624v1 [DOI]

14.

Indomethacin in Covid-19 [Internet]. ICR (UK) Limited t/a International Medical Information (IMI); [cited 2025 Aug 11]. Available from: https://medicalupdateonline.com/2020/05/indomethacincovid19/

15.

Rajah R, Subramanian S, Clark C. Low dose indomethacin for symptomatic treatment of COVID-19. Int J Med Rev Case Rep. 2020;4:69–70. [DOI]

16.

Krymchantowski AV, Silva-Néto RP, Jevoux C, Krymchantowski AG. Indomethacin for refractory COVID or post-COVID headache: a retrospective study. Acta Neurol Belg. 2022;122:465–9. [DOI] [PubMed] [PMC]

17.

Fazio S, Affuso F, Bellavite P. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19. Med Sci Monit. 2022;28:e936292. [DOI] [PubMed] [PMC]

18.

Checconi P, De Angelis M, Marcocci ME, Fraternale A, Magnani M, Palamara AT, et al. Redox-Modulating Agents in the Treatment of Viral Infections. Int J Mol Sci. 2020;21:4084. [DOI] [PubMed] [PMC]

19.

Lin CW, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, et al. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005;68:36–42. [DOI] [PubMed] [PMC]

20.

Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766–88. [DOI] [PubMed] [PMC]

21.

Haggag YA, El-Ashmawy NE, Okasha KM. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? Med Hypotheses. 2020;144:109957. [DOI] [PubMed] [PMC]

22.

Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol. 2020;11:1451. [DOI] [PubMed] [PMC]

23.

da Silva FMA, da Silva KPA, de Oliveira LPM, Costa EV, Koolen HH, Pinheiro MLB, et al. Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNA-dependent RNA polymerase (RdRp). Mem Inst Oswaldo Cruz. 2020;115:e200207. [DOI] [PubMed] [PMC]

24.

Liu Q, Huang N, Li A, Zhou Y, Liang L, Song X, et al. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine (Baltimore). 2021;100:e24544. [DOI] [PubMed] [PMC]

25.

Bianchi Porro G, Lazzaroni M, Petrillo M, Manzionna G, Montrone F, Caruso I. Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol. 1998;30:43–7. [PubMed]

26.

Carrasco-Pozo C, Castillo RL, Beltrán C, Miranda A, Fuentes J, Gotteland M. Molecular mechanisms of gastrointestinal protection by quercetin against indomethacin-induced damage: role of NF-κB and Nrf2. J Nutr Biochem. 2016;27:289–98. [DOI] [PubMed]

27.

Fan J, Li BR, Zhang Q, Zhao XH, Wang L. Pretreatment of IEC-6 cells with quercetin and myricetin resists the indomethacin-induced barrier dysfunction via attenuating the calcium-mediated JNK/Src activation. Food Chem Toxicol. 2021;147:111896. [DOI] [PubMed]

28.

Fazio S, Bellavite P, Zanolin E, McCullough PA, Pandolfi S, Affuso F. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021. Med Sci Monit. 2021;27:e935379. [DOI] [PubMed] [PMC]

29.

Ravichandran R, Mohan SK, Sukumaran SK, Kamaraj D, Daivasuga SS, Ravi SOAS, et al. An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients. Sci Rep. 2022;12:6413. [DOI] [PubMed] [PMC]

30.

Indomethacin for COVID-19: real-time meta-analysis of 4 studies [Internet]. CovidAnalysis; [cited 2025 Aug 14]. Available from: https://c19early.org/inmeta.html

31.

Desantis J, Mercorelli B, Celegato M, Croci F, Bazzacco A, Baroni M, et al. Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur J Med Chem. 2021;226:113814. [DOI] [PubMed] [PMC]

32.

Kiani P, Scholey A, Dahl TA, McMann L, Iversen JM, Verster JC. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021;13:558. [DOI] [PubMed] [PMC]

33.

Shekhar N, Kaur H, Sarma P, Prakash A, Medhi B. Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19. Expert Rev Anti Infect Ther. 2022;20:383–90. [DOI] [PubMed] [PMC]

34.

Desantis J, Bazzacco A, Eleuteri M, Tuci S, Bianconi E, Macchiarulo A, et al. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. Eur J Med Chem. 2024;268:116202. [DOI] [PubMed]

35.

Zeng X, Song X, Ma T, Pan X, Zhou Y, Hou Y, et al. Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. J Proteome Res. 2020;19:4624–36. [DOI] [PubMed]

36.

Wang Y, Li P, Xu L, de Vries AC, Rottier RJ, Wang W, et al. Combating pan-coronavirus infection by indomethacin through simultaneously inhibiting viral replication and inflammatory response. iScience. 2023;26:107631. [DOI] [PubMed] [PMC]

37.

Tramontozzi C, Riccio A, Pauciullo S, Frazia SL, Rossi A, Santoro MG. Indomethacin inhibits human seasonal coronaviruses at late stages of viral replication in lung cells: Impact on virus-induced COX-2 expression. J Virus Erad. 2024;10:100387. [DOI] [PubMed] [PMC]

38.

Covid-19, nuova circolare del Ministero aggiorna le linee guida per le cure domiciliari [Internet]. Ministero della Salute; [cited 2025 Jul 22]. Available from: https://www.salute.gov.it/new/it/news-e-media/notizie/covid-19-nuova-circolare-del-ministero-aggiorna-le-linee-guida-le-cure/

39.

Hvidberg E. Indomethacin. Nord Med. 1966;75:388–9. Danish. [PubMed]

40.

Chiabrando JG, Bonaventura A, Vecchié A, Wohlford GF, Mauro AG, Jordan JH, et al. Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:76–92. [DOI] [PubMed]

41.

Franklin IJ, Walton LJ, Greenhalgh RM, Powell JT. The influence of indomethacin on the metabolism and cytokine secretion of human aneurysmal aorta. Eur J Vasc Endovasc Surg. 1999;18:35–42. [DOI] [PubMed]

42.

Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2018;319:1221–38. [DOI] [PubMed] [PMC]

43.

Elmunzer BJ, Foster LD, Serrano J, Coté GA, Edmundowicz SA, Wani S, et al.; SVI Study Group. Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial. Lancet. 2024;403:450–8. [DOI] [PubMed] [PMC]

44.

Munjal A, Allam AE. Indomethacin. Treasure Island (FL): StatPearls Publishing; 2024. [PubMed]

45.

Amici C, Frazia SL, Brunelli C, Balsamo M, Angelini M, Santoro MG. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015;17:1391–404. [DOI] [PubMed] [PMC]

46.

Bourinbaiar AS, Lee-Huang S. The non-steroidal anti-inflammatory drug, indomethacin, as an inhibitor of HIV replication. FEBS Lett. 1995;360:85–8. [DOI] [PubMed]

47.

Rosztóczy I. Effect of indomethacin on the antiviral and priming effect of interferon. Acta Virol. 1978;22:254. [PubMed]

48.

Bahrami H, Daryani NE, Haghpanah B, Moayyeri A, Moghadam KF, Mirmomen S, et al. Effects of indomethacin on viral replication markers in asymptomatic carriers of hepatitis B: a randomized, placebo-controlled trial. Am J Gastroenterol. 2005;100:856–61. [DOI] [PubMed]

49.

Kapicioğlu S, Sari M, Kaynar K, Baki A, Ozoran Y. The effect of indomethacin on hepatitis B virus replication in chronic healthy carriers. Scand J Gastroenterol. 2000;35:957–9. [DOI] [PubMed]

50.

Ho P, Zheng JQ, Wu CC, Hou YC, Liu WC, Lu CL, et al. Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy. Int J Med Sci. 2021;18:314–24. [DOI] [PubMed] [PMC]

51.

Abdel Shaheed C, Beardsley J, Day RO, McLachlan AJ. Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection. Br J Clin Pharmacol. 2022;88:3114–31. [DOI] [PubMed]

52.

Mortezaei Z, Mohammadian A, Tavallaei M. Variations of SARS-CoV-2 in the Iranian population and candidate putative drug-like compounds to inhibit the mutated proteins. Heliyon. 2022;8:e09910. [DOI] [PubMed] [PMC]

53.

Gomeni R, Xu T, Gao X, Bressolle-Gomeni F. Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2. J Pharmacokinet Pharmacodyn. 2020;47:189–98. [DOI] [PubMed] [PMC]

54.

Marinella MA. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. Int J Clin Pract. 2020;74:e13535. [DOI] [PubMed] [PMC]

55.

Sorour K, El-Menshawy H. Indomethacin in COVID-19, more than just NSAID. ScienceOpen Preprints. 2021. [DOI]

56.

Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185. [DOI]

57.

Brunelli C, Amici C, Angelini M, Fracassi C, Belardo G, Santoro MG. The non-steroidal anti-inflammatory drug indomethacin activates the eIF2α kinase PKR, causing a translational block in human colorectal cancer cells. Biochem J. 2012;443:379–86. [DOI] [PubMed]

58.

Prasher P, Sharma M, Gunupuru R. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy. Drug Dev Res. 2021;82:469–73. [DOI] [PubMed] [PMC]

59.

Oh KK, Adnan M, Cho DH. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19. Sci Rep. 2021;11:9606. [DOI] [PubMed] [PMC]

60.

Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9:e59177. [DOI] [PubMed] [PMC]

61.

Haybar H, Maniati M, Saki N, Zayeri ZD. COVID-19: imbalance of multiple systems during infection and importance of therapeutic choice and dosing of cardiac and anti-coagulant therapies. Mol Biol Rep. 2021;48:2917–28. [DOI] [PubMed] [PMC]

62.

McCarthy CG, Wilczynski S, Wenceslau CF, Webb RC. A new storm on the horizon in COVID-19: Bradykinin-induced vascular complications. Vascul Pharmacol. 2021;137:106826. [DOI] [PubMed] [PMC]

63.

Alkotaji M, Al-Zidan RN. Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients? Curr Pharmacol Rep. 2021;7:102–6. [DOI] [PubMed] [PMC]

64.

Rodriguez-Portales JA, Lopez-Moreno JM, Mahana D. Inhibition of the kallikrein-kinin system and vascular reactivity in Bartter's syndrome. Hypertension. 1985;7:1017–22. [DOI] [PubMed]

65.

Abo Elmaaty A, Hamed MIA, Ismail MI, B Elkaeed E, S Abulkhair H, Khattab M, et al. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization. Molecules. 2021;26:3772. [DOI] [PubMed] [PMC]

66.

Tiwari Pandey A, Pandey I, Zamboni P, Gemmati D, Kanase A, Singh AV, et al. Traditional Herbal Remedies with a Multifunctional Therapeutic Approach as an Implication in COVID-19 Associated Co-Infections. Coatings. 2020;10:761. [DOI]

67.

Laughey W, Lodhi I, Pennick G, Smart L, Sanni O, Sandhu S, et al. Ibuprofen, other NSAIDs and COVID-19: a narrative review. Inflammopharmacology. 2023;31:2147–59. [DOI] [PubMed] [PMC]

68.

Giannis D, Douketis JD, Spyropoulos AC. Anticoagulant therapy for COVID-19: What we have learned and what are the unanswered questions? Eur J Intern Med. 2022;96:13–6. [DOI] [PubMed] [PMC]